Search results
Results from the WOW.Com Content Network
Acetylcholine Acetylcholinesterase Acetylcholinesterase inhibition. Acetylcholinesterase inhibitors (AChEIs) also often called cholinesterase inhibitors, [1] inhibit the enzyme acetylcholinesterase from breaking down the neurotransmitter acetylcholine into choline and acetate, [2] thereby increasing both the level and duration of action of acetylcholine in the central nervous system, autonomic ...
Anticholinergic drugs are used to treat a variety of conditions: Dizziness (including vertigo and motion sickness-related symptoms) Extrapyramidal symptoms, a potential side-effect of antipsychotic medications; Gastrointestinal disorders (e.g., peptic ulcers, diarrhea, pyloro spasm, diverticulitis, ulcerative colitis, nausea, and vomiting)
Acetylcholine is the neurotransmitter used at the neuromuscular junction—in other words, it is the chemical that motor neurons of the nervous system release in order to activate muscles. This property means that drugs that affect cholinergic systems can have very dangerous effects ranging from paralysis to convulsions.
Cholinergic blocking drugs are a group of drugs that block the action of acetylcholine (ACh), a neurotransmitter, in synapses of the cholinergic nervous system. [1] They block acetylcholine from binding to cholinergic receptors, namely the nicotinic and muscarinic receptors.
This muscarinic blocking effect is related to the acetylcholine moiety on the A ring on pancuronium. Making the N atom on the A ring tertiary, the ring loses its acetylcholine moiety, and the resulting compound, vecuronium, has nearly 100 times less affinity to muscarin receptors while maintaining its nicotinic affinity and a similar duration ...
A parasympathomimetic drug, sometimes called a cholinomimetic drug [1] or cholinergic receptor stimulating agent, [2] is a substance that stimulates the parasympathetic nervous system (PSNS). [3] [2] These chemicals are also called cholinergic drugs because acetylcholine (ACh) is the neurotransmitter used by the PSNS.
The drug has a relatively intermediate duration of action when compared to other non-depolarizing agents. [2] The drug has an onset of 2 to 3 minutes in adults and an expected peak effect at 3 to 5 minutes. [2] Recovery is expected to begin within 20 to 35 minutes of the initial dose, but it may take up to 70 minutes to achieve 95% recovery. [2]
These drugs work to increase the levels of acetylcholine and subsequently increase the function of neural cells. [8] However, not all treatments based upon the cholinergic hypothesis have been successful in treating the symptoms or slowing the progression of AD. [9]